Epidemiology of Nontuberculous Mycobacteria in Tuberculosis suspects, Southwest of China, 2017-2022

Front Cell Infect Microbiol. 2023 Oct 31:13:1282902. doi: 10.3389/fcimb.2023.1282902. eCollection 2023.

Abstract

Objectives: This study summarizes the epidemiological characteristics, species distribution, and drug sensitivity of clinical nontuberculous mycobacteria (NTM) isolates at the Public Health Clinical Center of Chengdu, China, from January 2017 to December 2022.

Methods: We retrospectively analyzed data from patients with clinically isolated NTM strains. Chi-square analysis assessed the rate of Mycobacterium strain isolation over 6 years.

Results: The number of samples tested for Mycobacterium tuberculosis (MTB) and/or NTM increased each year, while MTB detection decreased and NTM detection rose significantly each year (P=0.03). The average age of NTM patients was 51 ± 17.53 years, with a 14.1% HIV infection rate. The predominant isolates were Mycobacterium avium-intracellulare (MAC) and M. chelonae/M. abscessus, with 96.4% of cases being of Han ethnicity. Amikacin, moxifloxacin, and clarithromycin were effective against M. avium and M. intracellulare; linezolid, amikacin, and cefoxitin were effective against M. chelonae/M. abscessus. Over 90% of NTM cases originated from the respiratory tract.

Conclusion: The NTM isolation rate in Southwest China has risen in recent years, primarily among elderly patients with a high HIV co-infection rate. The main NTM isolates were MAC and M. chelonae/M. abscessus. Amikacin, moxifloxacin, clarithromycin, and linezolid exhibited strong antibacterial activity against SGM, while amikacin and linezolid displayed relatively better antibacterial activity against RGM. The prevalence of NTM infection may be positively associated with regional economic development and health conditions.

Keywords: NTM; TB; clinical characteristics; drug resistance; epidemiology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Amikacin / pharmacology
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • China / epidemiology
  • Clarithromycin / pharmacology
  • HIV Infections* / complications
  • HIV Infections* / epidemiology
  • Humans
  • Linezolid / pharmacology
  • Linezolid / therapeutic use
  • Microbial Sensitivity Tests
  • Middle Aged
  • Moxifloxacin / pharmacology
  • Mycobacterium Infections, Nontuberculous* / epidemiology
  • Mycobacterium Infections, Nontuberculous* / microbiology
  • Nontuberculous Mycobacteria
  • Retrospective Studies
  • Tuberculosis* / epidemiology

Substances

  • Clarithromycin
  • Amikacin
  • Linezolid
  • Moxifloxacin
  • Anti-Bacterial Agents

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by 2023 Chengdu Medical Research Project, Sichuan, China (202311013240) (to DMW).